The document discusses peptides that inhibit b2 glycoprotein 1 (b2-GP1) binding as a potential treatment for ischemia/reperfusion tissue damage seen in conditions like pre-eclampsia. The peptides have completed preclinical testing, preventing hemorrhage, reducing tumor size, and preventing pre-eclampsia in animal models. Further development would require sponsored research, licensing to a pharmaceutical company, scale-up production, clinical trials, and FDA approval.

1. Peptides for Preeclampsia
Treatment
April 26, 2017

2. What is the problem?
• Ischemia/reperfusion induces significant tissue
damage in multiple conditions
• One novel presentation of Ischemia/reperfusion is
elevated levels of b2-GP1
• Antibodies to b2-GP1 induce inflammation and tissue
damage.
• Therefore, inhibiting b2-GP1 inhibits inflammation and
tissue damage

3. How does product/service solve problem?
• Novel peptides inhibit b2 glycoprotein 1 (b2-GP1)
binding
IgM
B2GPI
Stressed cell

4. What is the market use?
• Mesenteric (intestinal) IR
• Myocardial IR
• Cancer
• Hemorrhage
• Pre-eclampsia

5. What competition exists?
• Complement inhibitors and peptides to non-muscle
myosin

6. What is the status of the intellectual property?
• US 8895502 B2
• β2-glycoprotein I
peptide inhibitors
• Issued
8,895,502

7. What is the stage of development?
• Preclinical
– Synthesized Peptides
• Do not aggregate
• Have a therapeutically effective half-life
– Cell Data
• Small enough to cross the cell membrane
• Safe and effective
– Animal Data
• Prevention of hemorrhage
• Reduction in tumor size
• Decrease in new blood vessel formation
• Prevention of pre-eclampsia
• Two peer-reviewed publications
• Reimbursement
– There are existing CPT codes in this area

8. What is needed for further development?
• Sponsored research
• License to a pharmaceutical
company
• Scale-up
• Clinical Trials
• FDA Approval